New York, July 14 -- Doctors Without Borders/Medecins Sans Frontieres (MSF) welcomes the release of new World Health Organization (WHO) HIV prevention guidelines recommending wider use of lenacapavir at the International AIDS Society Conference in Kigali, Rwanda.
The developer, Gilead Sciences, must now make it more accessible for people all over the world, said MSF. Access to this form of HIV prevention-an injectable version of pre-exposure prophylaxis (PrEP) that only needs to be administered two times per year-is especially critical as global health funding has been cut by the US and other donors, leaving fewer prevention programs and treatment options for those who fall ill.
"Lenacapavir is the kind of innovation that can be transform...